Eric Topol shares his firsthand experience with the Aktiia continuous blood pressure monitoring bracelet, a device designed to provide 24/7 automated readings using optical sensors. Despite promising early results and European regulatory approval, it still faces limitations, such as accuracy concerns with nighttime readings and insufficient diversity in study participants. While the device offers advantages like convenience, ease of use, and comprehensive data collection, Topol highlights the need for larger-scale validation studies before it can be considered a reliable alternative to traditional cuffs, especially in the U.S., where FDA approval is still pending.
Link to original article.
